Additionally, we assumed that anti‐CD96 could be considered in SCC treatment, whereas anti‐TIGIT and anti‐PD1 could be applied in ADC treatment according to the heterogenous expression of the aforementioned immune checkpoints in SCC and ADC tissues. Here, CD96 is linked to AIDS dementia complex.